Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
642-72-8
Molecular formula
C19H23N3O
Molecular weight
309.4 g/mol
Drug class
Topical indazole anti-inflammatory and analgesiclocal anaesthetic activity
Mechanism of action
Acts mainly through local anti-inflammatory effects, including inhibition of pro-inflammatory cytokine synthesis (notably TNF-α and IL-1β), membrane stabilisation and reduced neutrophil oxidative/granule responses. It is only a weak cyclo-oxygenase/lipoxygenase inhibitor at higher concentrations and also has local anaesthetic activity.
Indications / reported uses
Short-term local relief of pain and inflammation in the mouth and throat, including sore throat, pharyngitis, tonsillitis, oral ulcers and inflammation following dental procedures; formulation-specific use applies
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Benzydamine Environmental Risk Assessment (ERA) (the Benzydamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.